Search Bar & Filters
Found 67 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Researchers are evaluating TQB3107, a targeted inhibitor designed to induce cell death and stop tumor growth, in patients with advanced cancers. This Phase I clinical trial aims to assess the safety and tolerability of TQB3107 tablets, determine dose-limiting toxicities, find the maximum tolerated dose, and recommend a dose for future Phase II studies. Participants receive TQB3107 tablets following one of two dosing schedules either daily for five consecutive days each week with a two-day break per 28-day cycle, or intermittent dosing every 28 days. The study begins with an initial single fasting dose followed by a seven-day observation before continuing the dosing cycles. This design allows researchers to monitor participants closely during the first cycle to assess safety and dosing effects. During the study, participants will have regular assessments including pharmacokinetic blood sampling at multiple time points to measure drug levels, and evaluations of dose-limiting toxicities and maximum tolerated dose at the end of the first 28-day cycle. Longer-term outcomes such as response rates, disease control, progression-free survival, and overall survival will be followed for up to three years. Participants are monitored for up to 24 months for recommended dosing and safety, with comprehensive evaluations throughout the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for treating B-cell lymphoma. This Phase II clinical trial focuses on patients diagnosed with specific types of B-cell lymphoma, including relapsed or refractory indolent B-cell lymphoma and diffuse large B-cell lymphoma DLBCL. The study aims to assess how well this combination therapy works and its overall safety. Participants will receive TQB3702 tablets at a dose of 200 mg every 4 weeks as one treatment cycle. Alongside this, they will undergo chemotherapy cycles every 3 or 4 weeks, with a total of 6 to 12 cycles of combination therapy. The chemotherapy regimen is designed to inhibit tumor cell growth, suppress DNA synthesis, induce cancer cell death, support immune function, and prevent new blood vessel formation that supports tumors. During the trial, participants will be closely monitored for treatment response and safety. Researchers will measure overall and complete response rates up to 2 years, as well as adverse events, progression-free survival, duration of response, and overall survival up to death from any cause. The study includes assessments from baseline through combination therapy completion and follow-up periods lasting up to 2 years. This comprehensive monitoring helps understand both the immediate and longer-term effects of the treatment.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effects of TQF3250 capsules in adults with type 2 diabetes who are also overweight or obese. This Phase 1b, multi-center, randomized, double-blind, placebo-controlled study plans to enroll 72 participants divided into six dose groups ranging from 4 mg to 40 mg, with a dose-escalation design. Participants will take TQF3250 capsules or a matching placebo orally once daily under fasting conditions for 12 weeks. Each dose group includes 12 subjects, randomized in a 102 ratio to receive either the study drug or placebo. The dosing will follow a titration regimen, gradually increasing to the target dose. During the study, participants will have regular assessments including safety evaluations such as monitoring adverse events and clinical examinations. Pharmacokinetic measurements will be taken at multiple time points before and after dosing, while efficacy will be evaluated through tests like glycated hemoglobin HbA1c, oral glucose tolerance test, body weight, waist circumference, body mass index, fasting plasma glucose, C-peptide, and insulin levels. The total participation lasts about 14 weeks, including follow-up for safety and tolerability.
Actively Recruiting
Researchers are evaluating TQF3250 capsules in overweight or obese adults who have had difficulty controlling their weight despite simple lifestyle interventions. This Phase 1b, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, pharmacokinetic properties, and early signs of effectiveness of multiple doses of TQF3250. The trial involves 80 participants aged 18 to 65 years with specified BMI ranges and weight-related health issues. Participants are randomly assigned to one of six TQF3250 dose groups or a placebo group. Those in the treatment groups will gradually increase their dose from a low starting amount to the target dose, taking the capsules orally once daily for 12 weeks. The placebo group will also take capsules once daily for the same duration. The study monitors various pharmacokinetic parameters over several timepoints during the treatment period. Throughout the 12-week treatment, participants undergo regular assessments including body weight, body mass index, waist and hip measurements, blood sugar and insulin levels, blood pressure, and lipid profiles. Safety is monitored through adverse event tracking and clinical examinations from baseline up to 14 weeks. Pharmacokinetic blood sampling occurs at multiple intervals to analyze drug absorption and metabolism. Participants are expected to maintain lifestyle management, comply with medication schedules, and complete diaries and questionnaires during the study period.
Actively Recruiting
This research aims to evaluate the effects of TQH3906 Capsules in adults with active Psoriatic Arthritis PsA. The study plans to enroll 156 participants to assess how different doses of TQH3906 compare to placebo in improving PsA symptoms at Week 12, focusing on the proportion of participants reaching a 20% improvement according to the American College of Rheumatology criteria. Participants will be randomly assigned to receive one of several oral treatments daily from Day 1 to Day 169. These include 24 mg or 16 mg doses of TQH3906 capsules, a placebo phase followed by TQH3906, or an active comparator, Tofacitinib Citrate tablets. The study uses a double-blind design to compare these treatments effects and safety. Throughout the study, participants will attend visits for assessments including the ACR improvement criteria at multiple time points up to Day 169. Blood samples will be collected to evaluate drug levels and immune markers, and safety will be monitored closely. The main outcome is the proportion of participants achieving ACR20 response at Week 12. The study duration extends up to November 2027, with detailed evaluations of drug effects and adverse events throughout.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of TQB3019 capsules in adults with advanced malignant tumors. This Phase 1 clinical trial uses a single-center, open, non-randomized, single-arm design to study patients with recurrent or refractory hematological cancers. Participants must meet specific health criteria, including physical status and organ function, to join the study. Participants receive TQB3019 capsules orally once daily, with doses ranging from 25 to 600 mg depending on the group. The trial includes two phases dose escalation and dose expansion. Treatment cycles last 28 days, and dosing may be single or continuous. The study monitors various outcomes such as dose limiting toxicity, maximum tolerated dose, and recommended phase II dose, along with adverse events and response rates. During the trial, participants undergo regular assessments including pharmacokinetic sampling at multiple time points, evaluation of protein levels, and monitoring of adverse effects up to about three years. Researchers measure overall response rates, disease control, progression-free survival, and overall survival. Safety is closely tracked from the first dose until 28 days after the last dose or other anti-tumor treatments begin. The total study duration extends to approximately three years with ongoing follow-up.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Non-small cell lung cancer NSCLC is a common type of lung cancer where abnormal cells grow quickly, affecting lung function. This study focuses on advanced stages of squamous and nonsquamous NSCLC that cannot be surgically removed or have spread to other body parts. Researchers are investigating TAK-928, a new drug designed to activate immune cells called T cells to better attack and destroy tumor cells, comparing it to the standard treatment, docetaxel, in adults with this condition. TAK-928 is a bispecific monoclonal antibody administered through intravenous infusion that targets specific immune pathways to stimulate T cells and natural killer cells against cancer. Participants will receive either TAK-928 or docetaxel, also given by IV infusion. Treatment may continue for up to 24 months, with duration depending on individual response and side effects. The trial includes a randomized, parallel design to evaluate the efficacy and safety of TAK-928 compared to docetaxel. Participants will visit the study clinic multiple times for assessments including imaging scans to measure tumor response, laboratory tests, and questionnaires about quality of life and symptoms. Researchers will monitor treatment effects, side effects, and survival outcomes for up to 26 months. Safety and immune response will also be tracked throughout the study, with ongoing evaluations until treatment ends. Participant involvement may last up to two years or more depending on individual circumstances.
Actively Recruiting
Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.
1-10 of 67
1